ArticleBMC research notes2025
In-vivo evaluation of vitamin E loaded muscle void fillers for the provisional treatment of volumetric muscle loss.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study investigates the therapeutic potential of α-tocopherol (Vitamin E, VitE), delivered locally via a polyethylene glycol (PEG) hydrogel serving as a muscle void filler (MVF), for the acute treatment of volumetric muscle loss (VML) in a rat model. The primary goal was to determine if VitE, a reactive oxygen species scavenger, could exert antioxidant effects at the VML site and thereby improve the recovery of adjacent muscle tissue over a four-week period.
resultsThe MVF successfully increased VitE levels in the muscle throughout the implantation period. However, only the lowest concentration of VitE (5 mg/ml) showed a demonstrable effect, resulting in a 30% reduction in peak force compared to the PEG-alone group and a median muscle fiber size that was 4.34 μm smaller. Biochemical analysis revealed no differences in the expression of TGFβ1, protein carbonyl, or malondialdehyde across any groups. While local delivery of VitE was successful, further research is needed to optimize dosing and investigate additional mechanisms for improved muscle recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.